When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Robotic-arm assisted surgery using the Stryker Mako System may yield better functional results for total hip, as well as for partial or total knee replacement patients due to…
A recent study published in Lancet Neurology reveals important associations between MSH3 gene mutations and Huntington’s disease progression and disease burden.
Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Nicotinamide riboside appears to be the best precursor supplement available to help maintain or increase NAD+ levels. All cells and tissues can use it, and at high doses…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
